Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD –mutated AML

Blood (2025) 145 (19): 2138–2148.

https://doi.org/10.1182/blood.2024025154

Published: 2025

Includes: Supplemental data

Journal Articles

Financial Toxicity and Time Toxicity in Multiple Myeloma: Prevalence, Predictors, and Impact on QOL

Rahul Banerjee, Andrew J. Cowan, Marivel Chavez-Ortega, Paul A Carpenter, Masumi Ueda Oshima, Rachel B. Salit, Phuong T Vo, Catherine J. Lee, Rohtesh S. Mehta, Nicole M. Kuderer, Veena Shankaran, Stephanie J. Lee, Christopher T. Su

Blood (2023) 142 (Supplement 1): 2386.

https://doi.org/10.1182/blood-2023-174554

Published: 2023

Journal Articles

Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3-ITD Variant Allele Frequency and Survival Are Highly Correlated

Blood (2023) 142 (Supplement 1): 973.

https://doi.org/10.1182/blood-2023-177929

Published: 2023

Journal Articles

Effects of Severe Acute Graft-Versus-Host Disease on Quality of Life, Medical Comorbidities and Survival

Nahid Rashid, Albert Yeh, Marco Mielcarek, Masumi Ueda Oshima, Elizabeth F Krakow, Lynn E. Onstad, Laura Connelly-Smith, Phuong Vo, Stephanie J. Lee

Blood (2022) 140 (Supplement 1): 10552–10553.

https://doi.org/10.1182/blood-2022-167820

Published: 2022

Journal Articles

Characterization of Clonal Dynamics after Hematopoietic Cell Transplantation Using Ultra-Sensitive Duplex Sequencing

Jacob Higgins, PhD, Gabriel Pratt, PhD, Charles C. Valentine, MS, Lindsey N. Williams, PhD, Masumi Ueda, MD, Rainer Storb, MD, Jerald P. Radich, MD, Jesse J. Salk, MD PhD

Blood (2019) 134 (Supplement_1): 2483.

https://doi.org/10.1182/blood-2019-122490

Published: 2019

Journal Articles

Clonal Hematopoiesis in Donor-Recipient Pairs after Allogeneic Hematopoietic Cell Transplantation

Masumi Ueda, MD, Lan Beppu, Judy Campbell, RN, Mary E. D. Flowers, MD, Jerald P. Radich, MD, Rainer Storb, MD

Blood (2019) 134 (Supplement_1): 702.

https://doi.org/10.1182/blood-2019-126979

Published: 2019

Journal Articles

Predictors of 90-Day Mortality after Admission to Intensive Care Unit (ICU) in Patients with Acute Myeloid Leukemia (AML): Application of a Novel, Recently Validated AML-Specific Risk Model

Ylinne Lynch, MD, Shirali Agarwal, MD, Matthew Modes, MD MPP, Matthew Triplette, MD MPH, Masumi Ueda, MD, Barry E. Storer, PhD, Mary-Elizabeth M. Percival, MD MS, Pamela S. Becker, MD, Brenda M. Sandmaier, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD, Mohamed L. Sorror, MD MSc

Blood (2018) 132 (Supplement 1): 3986.

https://doi.org/10.1182/blood-2018-99-115419

Published: 2018

Journal Articles

Pilot Use of a Novel DNA Methytransferase -1 (DNMT1) Flow Cytometric Pharmacodynamic Assay to Evaluate Response to Low-Dose Azacitidine Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Hematopoietic Cell Transplantation

Najla H El Jurdi, MD, Masumi Ueda, MD MA, BA, Philip Woost, PhD, Hillard M Lazarus, MD, Paolo Caimi, MD, Brenda W. Cooper, MD, Richard Creger, PhD, Jane A. Little, MD, Linda Baer, MSN, NP-C, AOCNP, Lauren Brister, MSN, NP-C, AOCNP, Ehsan Malek, MD, Leland Metheny, MD, Folashade Otegbeye, MBBChir, MPH, Ben K. Tomlinson, MD, Basem M. William, MRCP,MD, James Jacobberger, PhD, Marcos De Lima, MD

Blood (2017) 130 (Supplement 1): 5503.

https://doi.org/10.1182/blood.V130.Suppl_1.5503.5503

Published: 2017

Journal Articles

Changes in Subcellular Localization of GSK3β As a Novel Driver of AML

James ignatz-Hoover, Isaac Ghansah, Masumi Ueda, MD, Victoria Wang, Hillard M Lazarus, MD, Marcos de Lima, MD, David Wald, PhD MD

Blood (2017) 130 (Supplement 1): 1226.

https://doi.org/10.1182/blood.V130.Suppl_1.1226.1226

Published: 2017

Journal Articles

Prognostic Impact of Morphological Cellularity in Early Assessment Bone Marrow Biopsy after 7+3 Induction in Patients with Acute Myeloid Leukemia

Fahrettin Covut, MD, Divya Gupta, MD, Raisa Pinto, MD, Nina Dambrosio, CNP, Najla H El Jurdi, MD, Masumi Ueda, MD MA, BA, Leland Metheny, MD, Brenda W. Cooper, MD, Paolo Caimi, MD, Ehsan Malek, MD, Folashade Otegbeye, MBBChir, MPH, Marcos De Lima, MD, Ben K. Tomlinson, MD

Blood (2017) 130 (Supplement 1): 1314.

https://doi.org/10.1182/blood.V130.Suppl_1.1314.1314

Published: 2017

Journal Articles

Glycogen Synthase Kinase-3 (GSK3) Inhibition with Lithium in Combination with Tretinoin Induces Differentiation in Non-Promyelocytic Acute Myeloid Leukemia (AML)

Masumi Ueda, MD, Paolo F. Caimi, MD, Tammy Stefan, Hillard M. Lazarus, MD, Brenda Cooper, MD, Marcos de Lima, MD, Stanton L. Gerson, MD, David N. Wald, MDPhD

Blood (2015) 126 (23): 1360.

https://doi.org/10.1182/blood.V126.23.1360.1360

Published: 2015

Journal Articles

The Use of Day 14 Bone Marrow Characteristics in the Decision to Pursue a Second Course of Induction Chemotherapy in the Treatment of Acute Myeloid Leukemia.

Masumi Ueda, M.D., Hu Xie, Ravinder K Sandhu, MD, Roland B. Walter, MD, PhD, John M. Pagel, MD, PhD, Pamela S. Becker, MD, PhD, Janis L. Abkowitz, MD, Elihu H. Estey, MD

Blood (2012) 120 (21): 2596.

https://doi.org/10.1182/blood.V120.21.2596.2596

Published: 2012

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD –mutated AML

Financial Toxicity and Time Toxicity in Multiple Myeloma: Prevalence, Predictors, and Impact on QOL

Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3-ITD Variant Allele Frequency and Survival Are Highly Correlated

Effects of Severe Acute Graft-Versus-Host Disease on Quality of Life, Medical Comorbidities and Survival

Characterization of Clonal Dynamics after Hematopoietic Cell Transplantation Using Ultra-Sensitive Duplex Sequencing

Clonal Hematopoiesis in Donor-Recipient Pairs after Allogeneic Hematopoietic Cell Transplantation

Predictors of 90-Day Mortality after Admission to Intensive Care Unit (ICU) in Patients with Acute Myeloid Leukemia (AML): Application of a Novel, Recently Validated AML-Specific Risk Model

Pilot Use of a Novel DNA Methytransferase -1 (DNMT1) Flow Cytometric Pharmacodynamic Assay to Evaluate Response to Low-Dose Azacitidine Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Hematopoietic Cell Transplantation

Changes in Subcellular Localization of GSK3β As a Novel Driver of AML

Prognostic Impact of Morphological Cellularity in Early Assessment Bone Marrow Biopsy after 7+3 Induction in Patients with Acute Myeloid Leukemia

Glycogen Synthase Kinase-3 (GSK3) Inhibition with Lithium in Combination with Tretinoin Induces Differentiation in Non-Promyelocytic Acute Myeloid Leukemia (AML)

The Use of Day 14 Bone Marrow Characteristics in the Decision to Pursue a Second Course of Induction Chemotherapy in the Treatment of Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only